NewAmsterdam Pharma (NAMS) Cash from Investing Activities (2023 - 2026)

NewAmsterdam Pharma has reported Cash from Investing Activities for 4 years, with the latest figure at -$11.5 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 503.12% year-over-year to -$11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189.3 million (down 217.54% YoY) and the FY2025 annual result came in at -$174.9 million, down 178.32% from the prior year.
• Cash from Investing Activities improved to -$11.5 million in Q1 2026 per NAMS's latest filing, from -$21.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $2.9 million in Q1 2025 and troughed at -$159.1 million in Q2 2025.
• A 4-year average of -$19.2 million and a median of -$75000.0 in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 2072533.33% in 2024, then surged 3441.33% in 2025.
• Over 4 years, Cash from Investing Activities stood at -$3000.0 in 2023, then plunged by 2072533.33% to -$62.2 million in 2024, then surged by 66.0% to -$21.1 million in 2025, then soared by 45.56% to -$11.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$11.5 million, -$21.1 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.